IN2014MN01183A - - Google Patents

Info

Publication number
IN2014MN01183A
IN2014MN01183A IN1183MUN2014A IN2014MN01183A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A IN 1183MUN2014 A IN1183MUN2014 A IN 1183MUN2014A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A
Authority
IN
India
Prior art keywords
formula
heteromultimers
compounds
mediated
therapy
Prior art date
Application number
Inventor
David Madge
Fiona Chan
Derek Edward John
Simon D Edwards
Richard Blunt
Basil Hartzoulakis
Lindsay Brown
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1119703.5A external-priority patent/GB201119703D0/en
Priority claimed from GBGB1214250.1A external-priority patent/GB201214250D0/en
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of IN2014MN01183A publication Critical patent/IN2014MN01183A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides compounds of formula (I): (Formula (I); wherein A R R R V X and Z are defined herein which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy in particular in treatment of diseases or conditions that are mediated by K3.1 and/or K3.4 or any heteromultimers thereof or that require inhibition of K3.1 and/or K3.4 or any heteromultimers thereof.
IN1183MUN2014 2011-11-15 2015-03-16 IN2014MN01183A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1119703.5A GB201119703D0 (en) 2011-11-15 2011-11-15 Compounds
GBGB1214250.1A GB201214250D0 (en) 2012-08-09 2012-08-09 Compounds
PCT/GB2012/052842 WO2013072694A1 (en) 2011-11-15 2012-11-15 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN01183A true IN2014MN01183A (en) 2015-07-03

Family

ID=47222145

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1183MUN2014 IN2014MN01183A (en) 2011-11-15 2015-03-16

Country Status (15)

Country Link
US (2) US9290511B2 (en)
EP (1) EP2780343A1 (en)
JP (1) JP2014533259A (en)
KR (1) KR20140094603A (en)
CN (1) CN104011054B (en)
AR (1) AR090037A1 (en)
AU (1) AU2012338570A1 (en)
BR (1) BR112014011671A2 (en)
CA (1) CA2855346A1 (en)
IN (1) IN2014MN01183A (en)
MX (1) MX2014005935A (en)
RU (1) RU2014124101A (en)
TW (1) TWI498331B (en)
WO (1) WO2013072694A1 (en)
ZA (1) ZA201403503B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509989VA (en) 2013-06-06 2016-01-28 Astellas Pharma Inc Benzothiophene compound
FR3015483B1 (en) 2013-12-23 2016-01-01 Servier Lab NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
RU2545758C1 (en) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Bicyclic pyrimides or their pharmaceutically acceptable salts - antioxidant programme activators and using them as cytoprotectors
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (en) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods and compositions for inhibiting the interaction of menin and mll proteins
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
FR3037959B1 (en) 2015-06-23 2017-08-04 Servier Lab NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037957B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037956B1 (en) * 2015-06-23 2017-08-04 Servier Lab NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037958B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CN106727587A (en) * 2016-11-28 2017-05-31 李娜 A kind of pharmaceutical composition for treating arrhythmia cordis
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
EA038388B1 (en) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Substituted inhibitors of menin-mll and methods of use
CN110691779B (en) 2017-03-24 2023-10-10 库拉肿瘤学公司 Approaches to Treating Hematologic Malignancies and Ewing's Sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
KR102736865B1 (en) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 Compounds that interact with the Ras superfamily for the treatment of cancer, inflammatory diseases, neurodevelopmental diseases and fibrotic diseases
EP3668841B1 (en) * 2017-08-14 2026-07-08 Acesion Pharma Aps Substituted benzimidazoles as potassium channel inhibitors
TW201920170A (en) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted MENIN-MLL inhibitor and method of use
MX2020005447A (en) 2017-11-27 2020-12-03 Dart Neuroscience Llc Substituted furanopyrimidine compounds as pde1 inhibitors.
CN108117556A (en) * 2018-01-15 2018-06-05 王山川 A kind of synthetic method of 1 inhibitor of cell-cycle checkpoint kinase
WO2020085504A1 (en) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 Method for producing chloroazole carboxylate derivative using sandmeyer reaction with light irradiation
JP7407461B2 (en) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー Compounds that interact with the RAS superfamily for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases
ES2974634T3 (en) 2018-12-21 2024-06-28 Celgene Corp Thienopyridine inhibitors of RIPK2
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel phenol compound or salt thereof
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
EP4313973A1 (en) * 2021-03-22 2024-02-07 Acesion Pharma ApS Novel potassium channel inhibitors
JP2024511801A (en) * 2021-03-26 2024-03-15 スミトモ ファーマ オンコロジー， インコーポレイテッド (furopyrimidin-4-yl)piperazine compounds and their uses
CA3218259A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
CN115006468B (en) * 2022-06-28 2023-06-06 西安外事学院 Compound Chinese herbal medicine hair-growing liquid and preparation method thereof
KR20260096846A (en) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Small molecule inhibitors of KRAS protein

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (en) 1990-03-19 1991-09-26 Basf Ag Thieno-(2,3-D)pyrimidine derivs. - are plant growth regulators, herbicides and pesticides, esp. insecticides
AU651337B2 (en) * 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
WO1998008845A1 (en) 1996-08-27 1998-03-05 Novartis Ag Herbicidal s-substituted 1,2,4,6-thiatriazines
WO2004011057A1 (en) 1998-02-07 2004-02-05 Advanced Cardiovascular Systems, Inc. Perfusion dilatation catherer with expanded support coil
JP2001097979A (en) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd Condensed heterocyclic compound, and method of production and application thereof
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9904738D0 (en) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10031585A1 (en) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-aminoalkyl-thieno [2,3-d] pyrimidine
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
IL159218A0 (en) 2001-06-25 2004-06-01 Nissan Chemical Ind Ltd Substituted benzopyran derivatives against arrhythmia
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
ES2217956B1 (en) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF 4-AMINOTIENE (2,3-D) PIRIMIDIN-6-CARBONITRILE.
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
CN1823071B (en) * 2003-06-11 2012-12-19 润生有限公司 Thienopyrimidine derivatives as potassium channel inhibitors
US7594219B2 (en) 2003-07-24 2009-09-22 International Business Machines Corporation Method and apparatus for monitoring compatibility of software combinations
TWI346112B (en) 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
TW200609237A (en) * 2004-04-12 2006-03-16 Sankyo Co Thienopyridine derivatives
CA2568304A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006047397A1 (en) 2004-10-21 2006-05-04 Dow Agrosciences Llc Thieno-pyrimidine compounds having fungicidal activity
US7576212B2 (en) * 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
ATE476434T1 (en) * 2004-12-09 2010-08-15 Xention Ltd THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
CA2595882A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
WO2006100591A1 (en) 2005-03-25 2006-09-28 Pharmacia & Upjohn Company Llc 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
EP1896483A2 (en) 2005-03-28 2008-03-12 Pharmacia & Upjohn Company LLC 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602538A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602227A1 (en) 2005-03-28 2006-10-05 Michael Dalton Ennis 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
US7816351B2 (en) * 2005-09-23 2010-10-19 Equispharm Co., Ltd 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP2043654A2 (en) * 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thienopyrimidines useful as modulators of ion channels
DE102006030236A1 (en) 2006-06-30 2008-01-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Direct oxidation fuel cell for convection-free transport of the fuel and method for operating the fuel cell
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TW200924781A (en) * 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PL2254873T3 (en) 2008-02-22 2014-10-31 Otsuka Pharma Co Ltd Benzodiazepine compound and pharmaceutical composition
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
BRPI0918971A2 (en) * 2008-08-26 2015-12-01 Boehringer Ingelheim Int thienopyrimidines for pharmaceutical compositions
TWI334124B (en) * 2008-08-28 2010-12-01 Au Optronics Corp Display drive circuit for flat panel display and driving method for gate lines
TWI389913B (en) 2008-09-08 2013-03-21 Lg Life Sciences Ltd Fused heterocyclic compound
AR073739A1 (en) 2008-09-10 2010-12-01 Kalypsys Inc AMINOPIRIMIDINS AS INHIBITORS OF HISTAMINE RECEPTORS
WO2010033127A1 (en) 2008-09-22 2010-03-25 Sionyx, Inc. Response-enhanced monolithic-hybrid pixel
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
JP5619907B2 (en) 2009-10-29 2014-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Quinuclidine compounds as α7 nicotinic acetylcholine receptor ligands
CA2788450A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20140094603A (en) 2014-07-30
NZ626199A (en) 2015-04-24
AR090037A1 (en) 2014-10-15
US9290511B2 (en) 2016-03-22
TWI498331B (en) 2015-09-01
MX2014005935A (en) 2014-09-04
TW201326178A (en) 2013-07-01
BR112014011671A2 (en) 2017-05-30
US20160152634A1 (en) 2016-06-02
ZA201403503B (en) 2016-09-28
US20140371203A1 (en) 2014-12-18
CN104011054B (en) 2016-08-24
JP2014533259A (en) 2014-12-11
CN104011054A (en) 2014-08-27
AU2012338570A1 (en) 2014-07-03
WO2013072694A1 (en) 2013-05-23
CA2855346A1 (en) 2013-05-23
EP2780343A1 (en) 2014-09-24
RU2014124101A (en) 2015-12-27

Similar Documents

Publication Publication Date Title
IN2012DN00971A (en)
IN2014KN00769A (en)
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX343534B (en) Inhibitors of arginase and their therapeutic applications.
AU2012214029A8 (en) Rorgammat inhibitors
MD20150043A2 (en) Inhibitors of histone demethylases
UA118610C2 (en) Spirocyclic inhibitors of cathepsin c
MX2012003644A (en) 2-pyridone compounds used as inhibitors of neutrophil elastase.
IN2014DN10670A (en)
IN2014CN04907A (en)
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2014MN00988A (en)
EA201291099A1 (en) NEW IMMUNODULATOR AND ANTI-INFLAMMATORY CONNECTIONS
MY172924A (en) Neprilysin inhibitors
MX2020001602A (en) Lfa-1 inhibitor and polymorph thereof.
SG10201811204RA (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
JO2998B1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
MX2013008192A (en) Bace-2 inhibitors for the treatment of metabolic disorders.
IN2014CN04676A (en)
IN2014MN00948A (en)
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2017004618A (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases.
GEP20135964B (en) Inhibitors of beta-secretase
MY167898A (en) Co-crystals and salts of ccr3-inhibitors